Cancer Pathophysiology
A section of Cancers (ISSN 2072-6694).
Section Information
The major abnormality driving the development of all cancer types is the dysregulated proliferation of cancer cells that grow and divide in an uncontrolled manner, invading normal tissues and organs and eventually spreading throughout the body. Such loss of control in growth is the net result of the accumulation of abnormalities in diverse regulatory systems, resulting in such modifications of cell behavior that distinguish cancerous from normal cells.
Cancer development has historically been seen as a multistep process involving mutation and selection for cells with a progressively increasing capacity for proliferation, survival, invasion, and metastasis. The first step in this process, referred to as tumor initiation, is considered to result from a genetic alteration leading to abnormal proliferation and the generation of a population of clonally derived tumor cells. Further mutations progressively accumulate and are responsible for tumor progression, which confers the so-called property of clonal selection that continues throughout tumor development.
In parallel, more recent findings indicate that epigenetic changes as well as alterations in the noncoding RNA repertoire may occur and significantly contribute to both the initiation and progression of cancer.
This section of Cancers aims to publish contributions on all aspects of cancer pathophysiology. We encourage the submission of all types of manuscripts, including original articles, narrative and systematic reviews, and communications reporting significant advances in the pathophysiology of solid and hematologic cancers. Topics include, but are not limited to:
- Cancer biology
- Cancer dependency
- Cancer epigenetics
- Cancer phenotype
- Cancer genetics
- Cancer-associated miRNAs
- Cancer stem cells
- Cancer translational research
- Cancer-associated noncoding RNAs
- DNA damage
- DNA repair systems
- Hematological cancers
- Metastasis
- Oncogenes
- Pre-malignant conditions
- Signal transduction pathways
- Solid cancers
- Targeted anticancer therapy
- Tumor angiogenesis
- Tumor differentiation
- Tumor suppressor genes
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Histology and Pathology of Pancreatic Cancer (Deadline: 30 September 2024)
- Histopathology of Urological Cancers (Deadline: 30 September 2024)
- Interplay between Signaling Pathways and Metabolism in Brain Tumors (Deadline: 30 September 2024)
- Endoscopic Ultrasound in Cancer Research (Deadline: 5 October 2024)
- Pathology of Gynecological Cancers (Deadline: 15 October 2024)
- Multi-Omics Analysis in the Study of Carcinogenesis (Deadline: 15 October 2024)
- Pathology of Acute Myeloid Leukemia (AML) (Deadline: 25 October 2024)
- Metabolic Syndrome in Cancer (Deadline: 31 October 2024)
- Pathology of Hematologic Malignancies (Deadline: 31 October 2024)
- Colorectal Cancer Metastasis (Volume II) (Deadline: 10 November 2024)
- Updates on Epigenetics of Brain Tumor (Deadline: 30 November 2024)
- Prognostic and Predictive Factors in Advanced Gastro-Intestinal Cancers (Deadline: 10 December 2024)
- Digital Pathology Systems Enabling the Quality of Cancer Patient Care (Deadline: 15 December 2024)
- Pathogenesis of Non-alcoholic Steatohepatitis (NASH)-Related Hepatocellular Carcinoma (HCC) (Deadline: 27 December 2024)
- Epigenetics and Transcription Networks in Leukemia (Deadline: 30 December 2024)
- Hereditary and Familial Colorectal Cancer (Deadline: 31 December 2024)
- Advances in Genomics and Molecular Pathology of Rare Cancers—Focus on Diverse Populations (Deadline: 31 December 2024)
- Genomic Landscape of Myelodysplastic Syndromes (Deadline: 31 December 2024)
- Oncogenetics of Colorectal Cancer (Deadline: 31 December 2024)
- Advances in the Molecular Pathogenesis of T-cell Lymphoma (Deadline: 31 December 2024)
- Urogenital Neoplasms Pathology (Deadline: 31 December 2024)
- RNA in Non-Small-Cell Lung Cancer (Deadline: 31 December 2024)
- Clear Cell Renal Cell Carcinoma 2024–2025 (Deadline: 31 December 2024)
- Molecular Mechanisms and Pathophysiology of Oral Cancer (Deadline: 31 January 2025)
- Genetics and Epigenetics of Gynecological Cancer (Deadline: 31 January 2025)
- Pathology and Treatment of Triple-Negative Breast Cancer (Deadline: 31 January 2025)
- The Role of NPM1 Mutation in Acute Myeloid Leukemia (Deadline: 1 February 2025)
- Pathology, Diagnosis and Treatment in Non-small Cell Lung Cancer (Deadline: 17 February 2025)
- Genetic, Epigenetic, and Epitranscriptomic Changes in Lung Cancer (Deadline: 31 March 2025)
- Cancer and Chronic Illness (Deadline: 15 April 2025)
- Clinical Pathology of Lung Cancer (Deadline: 15 April 2025)
- Lymphoma Biology, Pathology and Stem Cells (Deadline: 15 May 2025)
- The Pathology of Biliary Tract Carcinoma (BTC) (Deadline: 20 May 2025)
- Molecular Diversity of Gliomas: Epidemiology, Pathology and Genetic/Epigenetic Heterogeneity (Deadline: 1 June 2025)
- Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia (Deadline: 30 June 2025)
- Cancer Smart Nanomedicine (2nd Edition) (Deadline: 30 June 2025)
- Advances in Spinal Tumoral Pathology: Surgical Perspectives and Multidisciplinary Therapeutic Approaches (Deadline: 20 July 2025)
- Advances in the Pathogenesis of Hematopoietic Neoplasms (Deadline: 31 December 2025)